# Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Anti-Filovirus Therapeutics
**AGENCY:**
Department of the Army, DoD.
**ACTION:**
Notice.
**SUMMARY:**
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/761,942, entitled “Anti-Filovirus Therapeutics,” filed on February 7, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
**ADDRESSES:**
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.
**FOR FURTHER INFORMATION CONTACT:**
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.
**SUPPLEMENTARY INFORMATION:**
The invention relates to an antisense oligonucleotide directed to a mRNA encoding a mammalian Niemann-Pick C1 (NPC1) receptor, and combinations thereof and compositions comprising such are provided. Also provided are methods of treating or reducing filovirus infection of a subject.
Brenda S. Bowen,
Army Federal Register Liaison Officer.